急性単純性膀胱炎に対するCefixime(セフスパン)の使用経験

Abstract

成人女子の急性単純性膀胱炎154例に対しCFIXを投与しその治療成績ならびに安全性につき検討した.1) UTI薬効評価基準を満たした94例での総合臨床効果は著効76例, 有効17例, 無効1例であり, 有効率は98.9%であった.2)臨床症状, 膿尿および細菌尿に対する効果はそれぞれ98.9%, 97.9%, 97.9%であった.3)副作用は1例に頭重感がみられたのみで, 臨床検査値異常は3例にみられた.4)急性単純性膀胱炎に対しCFIXは有用かつ安全な薬剤と思われた

Cefixime (CFIX) was administered 200 mg (2 divided doses) per day to 154 female patients with acute uncomplicated cystitis. Ninety four of the 154 patients who satisfied the criteria proposed by the UTI Committee, Japan were examined for the efficacy of the treatment, but 151 of 154 patients were included in the study of the side effects of the drug. The overall clinical efficacy was excellent in 80.8% and moderate in 18.1% of the patients. Ninety five (97.9%) of 97 strains which were isolated from the patients were eradicated in the urinary specimens by the treatment. Subjective side effects were observed in only one (0.7%) of the 151 patients, who complained of a sensation of heaviness in the head. No drug-related aggravation in the laboratory test was observed except for three patients who showed mild elevation glutamic pyruvic transaminase, alkaline phosphatase and blood urea nitrogen. These results showed that the oral administration of CFIX was excellent and satisfactory in the treatment for acute uncomplicated cystitis.